Stem Cell Institute in Panama Collaborates on New Method of Treating Diabetes-Associated Heart Disease

Zhang et al. Journal of Translational Medicine

Diabetes is associated with numerous “secondary complications” including premature heart disease, renal failure, critical limb ischemia (an advanced form of peripheral artery disease) and diabetic retinopathy. One of the common features of these secondary complications is that they are all associated with low levels of circulating endothelial progenitor cells. We have previously discussed the interaction between inflammation and low levels of circulating endothelial progenitor cells http://www.translational-medicine.com/content/7/1/106. It appears that the uncontrolled sugar levels in the blood cause generation of modified proteins, which initiate low level, chronic inflammation. One of the major mechanisms by which sugar- modified proteins induce inflammation is by stimulating a molecular signaling protein called Toll like receptor (TLR)-4. Generally TLR-4 is used by the body to sense “danger”, that is, to sense pathogens, tissue injury, or various factors that may negatively affect the well-being of the host.

In a collaborative study between Stem Cell Institute Panama, Medistem, and the University of Western Ontario, Canada, it was observed that TLR-4 is associated with induction of heart cell (cardiomyocyte) death in diabetic animals. The scientists demonstrated that suppressing the gene encoding for TLR-4 resulted in prevention of heart disease. The results were published in the article Zhang et al. Prevention of hyperglycemia-induced myocardial apoptosis by gene silencing of Toll-like receptor-4. J Transl Med. 2010 Dec 15;8(1):133. TLR-4 is known to recognize bacterial endotoxin, fragments of degraded extracellular matrix, as well as the stress protein HMBG-1.

In the current experiment, mice were made diabetic by administration of the islet-specific toxin streptozotocin. Diabetic mice were treated with double stranded RNA specific to the gene encoding TLR4. It is known that when cells are treated with double stranded RNA, the gene that is similar to the double strand is silenced. This process is called “RNA interference”.

Seven days after mice became diabetic, as evidenced by hyperglycemia, the level of TLR4 gene in myocardial tissue was significantly elevated. This suggested that not only does hyperglycemia activate TLR4, which was previously known, but that expression of this pro-inflammatory marker actually is increased. Indeed it may be possible that triggers of TLR4 actually act in an autocrine manner in order to increase cell sensitivity

In order to determine whether TLR4 was associated with the cause of cardiomyocyte death, animals were administered the double stranded RNA in order to suppress levels of TLR4. When this was performed the level of cardiomyocyte death was markedly reduced. This is an important finding since usually scientists think of TLR4 as a molecule that activates inflammation through stimulation of the immune

The authors conclude by stating that new evidence is presented suggesting that TLR4 plays a critical role in cardiac apoptosis. This is the first demonstration of the prevention of cardiac apoptosis in diabetic mice through silencing of the TLR4 gene.

The research finding that TLR4 is implicated in death of cardiac cells means that agents that suppress it, such as double stranded RNA, may be useful for incorporation into stem cells in order to make the cardiac cells that are derived from the stem cells resistant to death induced by conditions of stress such as hyperglycemia.

Stem Cell Institute Stem Cell Clinic Publishes Successful Treatment of Heart Failure Patient

PANAMA CITY, PANAMA – The Stem Cell Institute reported today publication in the peer reviewed journal, International Archives of Medicine, of a heart failure patient who underwent profound recovery after receiving adult stem cell therapy. The publication is freely available at www.intarchmed.com.

“Stem cell therapy is experimental, and although the results discussed in the paper are promising, only the conduct of double-blinded, placebo controlled trials, will allow definitive conclusions to be drawn”, said Dr. Paz Rodriguez, Medical Director of the Cellmedicine Panama clinic and coauthor of the study.

The heart failure patient described in the study received stem cell therapy on November 2007, presenting with an ejection fraction of 25-30%. At follow-ups on June 2008, August, and Oct 2009, the ejection fraction stabilized at 40%. A major improvement in quality of life was reported. Biochemical markers of heart failure decreased. No treatment associated adverse reactions were noted.

“To date our group has published results on multiple sclerosis, non-ischemic heart failure, and Duchenne Muscular Dystrophy patients in collaboration with major American Universities including University of California San Diego, Indiana University, and University of Utah. By publishing our data in a scientific forum, we welcome discussion and interaction, which will lead to advanced patient care not only in Panama City but internationally.” Concluded Dr. Paz Rodriguez.

The Cellmedicine Institutes offer adult stem cell therapy for patients suffering from a variety of degenerative conditions. More information is available at www.cellmedicine.com.

Statement From The Stem Cell Institute Regarding Decision to Close Costa Rican Operations

The Stem Cell Institute announced today that it proactively and independently made the business decision in early June to close its clinic and lab in Costa Rica and centralize all operations in Panama City, Panama. This decision was made voluntarily.

This decision, which came after careful consideration, was reached in response to Costa Rica’s unpredictable and arbitrary regulatory landscape. During its time in Costa Rica the company operated in full compliance with all existing laws and regulations. Unfortunately, however, the recent lack of clarity regarding adult stem cell treatment regulation in Costa Rica proved to be too great a risk for The Stem Cell Institute to continue its work in that country.

The Stem Cell Institute maintains the highest standards of ethics, transparency and consistency. Its adult stem cell therapy treatments are conducted with the strictest adherence to legal, ethical and industry guidelines. All cells used in treatments are processed in accordance with Current Good Tissue Practices (cGTP) in a state-of-the-art laboratory that is fully licensed and certified. Our staff is comprised of highly trained doctors and other medical specialists who have dedicated years to uncovering new treatments to aid those challenged by chronic diseases for which there are inadequate standard therapies.

The company came to this decision with much regret and will dearly miss its colleagues, patients and friends in Costa Rica. In just four years, The Stem Cell Institute helped hundreds of people who are challenged with chronic diseases such as Cerebral Palsy, Multiple Sclerosis, Osteoarthritis, Rheumatoid Arthritis, Muscular Dystrophy, and Spinal Cord Injury.

The company’s commitment to helping patients with chronic diseases benefit from new, cutting edge adult stem cell therapies is unchanged. It has a vibrant, growing clinic in Panama City that has already served more than 150 since opening in 2007. The government of Panama has clearly-defined laws that regulate adult stem cell therapies. Moreover, Panama City is an easily accessible metropolitan city with world-class facilities and accommodations to better serve our patients. The Stem Cell Institute’s facilities in Panama are fully licensed and certified.